CH BIOTECH SER (08037): Hubei Weiyu intends to invest up to 50 million yuan in Pengbo (Hainan).

CH BIOTECH SER (08037) announced on February 27, 2025 that Pengbo (Hainan), DYNAM JAPANic Healthcare, Pengbo, the company, and Hubei Weiyu have entered into a capital injection agreement. All parties conditionally agreed to increase Pengbo (Hainan)'s registered capital from 150 million yuan (approximately 162 million Hong Kong dollars) to 167 million yuan (approximately 180 million Hong Kong dollars); and Hubei Weiyu agreed to inject up to 50 million yuan (approximately 54 million Hong Kong dollars) into Pengbo (Hainan) to subscribe for 10% of the enlarged registered capital, amounting to 16.67 million yuan (approximately 18 million Hong Kong dollars). Of the injection amount of 50 million yuan (approximately 54 million Hong Kong dollars), 16.67 million yuan (approximately 18 million Hong Kong dollars) will be credited as Pengbo (Hainan)'s registered capital, and the remaining 33.33 million yuan (approximately 36 million Hong Kong dollars) will be credited to the share premium account. The company believes that the capital injection agreement and the transactions to be conducted under it will provide more funding for the development of the Boron-Neutron Capture Therapy Center. In addition, the funds raised from the capital injection of up to 50 million yuan (approximately 54 million Hong Kong dollars) are expected to be used to repay Pengbo (Hainan)'s existing loans; and for the construction, development, and operation of the Boron-Neutron Capture Therapy Center.